nonprofit, tuberculosis, industry
Blue Rush: One Company Leads the Race to Own Marine Genetic Sequences
Blue Rush: One Company Leads the Race to Own Marine Genetic Sequences
Ruth Williams | Jun 6, 2018
Almost half of all patents relating to the genes of marine organisms belong to one large international corporation, BASF, a new study reveals.  
How to Successfully Collaborate with Industry
How to Successfully Collaborate with Industry
Ashley P. Taylor | Mar 1, 2018
In efforts to translate basic-science results into pharmaceuticals and other technologies, success cannot be taken for granted.
Investigation Questions Transparency for Failed TB Vax
Investigation Questions Transparency for Failed TB Vax
Jef Akst | Jan 11, 2018
The BMJ inquiry finds that researchers presented only select results from animal experiments when applying for funding and approval for human trials.
Urine Test for TB Yields Results in 12 Hours
Urine Test for TB Yields Results in 12 Hours
Jef Akst | Dec 14, 2017
The new test could improve upon two current methods to diagnose tuberculosis—a skin test or culturing bacteria from saliva, both of which take days.
Can Young Stem Cells Make Older People Stronger?
Can Young Stem Cells Make Older People Stronger?
Shawna Williams | Dec 11, 2017
Small trials using younger donors and elderly recipients hint that mesenchymal stem cell transfers might reduce frailty. 
Editors Claim Censorship at a Public Health Journal
Editors Claim Censorship at a Public Health Journal
Jef Akst | Nov 21, 2017
The editorial board at the International Journal of Occupational and Environmental Health accuses its publisher of promoting corporate interests.
2017 Life Science Salary Survey
2017 Life Science Salary Survey
Aggie Mika | Nov 1, 2017
Industry professionals make more than academic researchers, but for professors, it may not be about the money.
Opinion: Tales from the Nonacademic Career Path
Opinion: Tales from the Nonacademic Career Path
Anna Kriebs | Sep 3, 2017
Graduate students from The Scripps Research Institute share how they prepared to enter policy, law, biotech, and beyond.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Life Science Leaders Meet at White House
Life Science Leaders Meet at White House
Kerry Grens | May 8, 2017
Heads of academia and industry mingled with the vice president and the secretary of Health and Human Services at a biotech summit.